综合来看，这项研究意义非凡。研究人员通过 CRISPR/Cas 技术实现了高效的基因编辑，获得的 T 细胞既具有强大的靶向特异性，又对糖皮质激素具有抗性。这不仅为治疗移植后 EBV 激活或 EBV 相关疾病提供了新的治疗选择，也为 GMP 兼容的 CRISPR/Cas 工程生成抗糖皮质激素的 CAR-T 细胞产品奠定了基础。不过，目前该研究仍处于前期阶段，这种一体化的 gp350-CAR GR ...

Suffering on such an immense scale can appear hopeless. However, a technique called CRISPR gene editing promises to help deal with these issues and many more—and wise regulation can spur it on.

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

Using gene editing with CRISPR-Cas9, the team has been able to study these proteins without altering ... Dec. 13, 2024 — Microorganisms produce a wide variety of natural products that can be ...

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell.

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing ...

CRISPR technology has revolutionized genetic testing and disease detection, offering precise, rapid, and cost-effective diagnostic solutions. This gene-editing tool has been adapted for molecular ...

GenScript now provides high-quality, sequence-verified HDR templates to help users edit their CRISPR experiments more effectively. At a GMP-compatible scale, the KI efficiency of GenExact™ ssDNA ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

CRISPR Therapeutics AG (CRSP) closed at $41.17 in the latest trading session, marking a -1.84% move from the prior day. Biotech is an area that may offer your portfolio growth today and earnings ...

Crispr Therapeutics AG reported significant revenue declines in Q4 and FY24 due to reduced collaboration revenues, but maintains strong financial health with $298m cash and $1.6bn in marketable ...